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Ischemia reperfusion injuryOnce a virtually unknown nitrogen oxide, nitroxyl (HNO) has emerged as a potential pharmacological agent.
Recent advances in the understanding of the chemistry of HNO has led to the an understanding of HNO
biochemistry which is vastly different from the known chemistry and biochemistry of nitric oxide (NO), the
one-electron oxidation product of HNO. The cardiovascular roles of NO have been extensively studied, as NO
is a key modulator of vascular tone and is involved in a number of vascular related pathologies. HNO displays
unique cardiovascular properties and has been shown to have positive lusitropic and ionotropic effects in
failing hearts without a chronotropic effect. Additionally, HNO causes a release of CGRP and modulates
calcium channels such as ryanodine receptors. HNO has shown beneﬁcial effects in ischemia reperfusion
injury, as HNO treatment before ischemia-reperfusion reduces infarct size. In addition to the cardiovascular
effects observed, HNO has shown initial promise in the realm of cancer therapy. HNO has been demonstrated
to inhibit GAPDH, a key glycolytic enzyme. Due to the Warburg effect, inhibiting glycolysis is an attractive
target for inhibiting tumor proliferation. Indeed, HNO has recently been shown to inhibit tumor proliferation
in mouse xenografts. Additionally, HNO inhibits tumor angiogenesis and induces cancer cell apoptosis. The
effects seen with HNO donors are quite different from NO donors and in some cases are opposite. The
chemical nature of HNO explains how HNO and NO, although closely chemically related, act so differently in
biochemical systems. This also gives insight into the potential molecular motifs that may be reactive towards
HNO and opens up a novel ﬁeld of pharmacological development.Published by Elsevier B.V.1. Introduction
Nitrogen oxides are important components of many physiological
processes andwith respect to cardiovasculardiseases, have thepotential
to be useful pharmacological agents. The advent of nitrovasodilators
such as nitroglycerin and the discovery that nitric oxide (NO) is
endothelial derived relaxation factor (EDRF) has lead to an increase of
research in this ﬁeld. In the cardiovascular system, nitric oxide has been
shown to regulate vascular tone, platelet function, leukocyte adhesion
and extravasations of leukocytes [1,2]. Dysfunction in the NO/cGMP
pathway leads to a number of cardiovascular disorders [3,4]. In addition
to the critical functions of NO in the circulatory system, nitric oxide plays
a role in the control of heart function [5].1 301 480 2238.
ih.gov (D.A. Wink).
B.V.One of the complexities of studying NO is the diverse array of other
nitrogen oxides that must be considered since NO metabolism can
result in species such as nitrate, nitrite, peroxynitrite, nitrogen
dioxide, hydroxylamine and ammonia. One of the most overlooked,
yet chemically simple nitrogen oxide is HNO (colloquially termed
nitroxyl; nitrosyl hydride in the IUPAC nomenclature), which is the
one-electron reduction product of NO. In comparison, HNO is to NO as
superoxide (O2−) is to molecular oxygen (O2) (Fig. 1). Both NO and O2
are stable paramagnetic gases with neutral charge and one-electron
reduction to HNO/NO− or O2−, respectively, results in the formation
of an anion. In aqueous conditions, the formed anion has a pKa
associated with the equilibrium of protonation of the anion. For
superoxide, a pKa of 6.8 has been measured, while the pKa of NO− has
been calculated to be around 11.4 (the HNO/NO− acid–base
equilibrium is more complicated than common Brönsted–Lowry
acid–base conjugates and will be discussed below in more detail).
The electrochemical reduction of O2 to O2− is thermodynamically
Fig. 1. Comparison of HNO and superoxide chemistry. (A) Molecular oxygen (O2)
reduction to superoxide (O2−) is thermodynamically unfavorable, as is the reduction of
NO to HNO/NO−. Further reduction of O2− to hydrogen peroxide is thermodynamically
favorable, as is the reduction of HNO. (B) Reduction of O2 or NO results in an anionic
species that has an associated pKa in aqueous conditions. Superoxide has a pKa of 4.88
and in neutral conditions the anion is the predominant species. Nitroxyl has a pKa of
11.4 and the dominant species in biology will be HNO. (C) Superoxide and HNO both
auto-react resulting in the destruction of these species.
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NO− is thermodynamically very unfavorable (E°=−0.8 V) while
reduction to HNO is still unfavorable (E°=−0.6 V) [6]. Just asTable 1
Common HNO donors used in biology.
Donor Chemical structure
Angeli's salt
Piloty's acid
Acyloxo nitroso “blue compounds”
IPA/NO
Hetero-Diels–Alder cycloadductsuperoxide is easily reduced to hydrogen peroxide (E=+0.89 V vs.
NHE, pH 7), HNO can also be reduced to hydroxylamine as the two-
electron reduction potential has been calculated to be approximately
E°=+0.8 V [7]. Additionally, the one-electron reduction of HNO to
aminoxyl radical (NH2O) has been calculated and is also thermo-
dynamically favorable (E°=+0.6 V) [7]. Another comparison lies
with the self-destruction of both superoxide and HNO; superoxide is
known to undergo spontaneous disproportionation (i.e. two mole-
cules of superoxide react to form molecular oxygen and hydrogen
peroxide) while two molecules of HNO react to form essentially an
HNO dimer (hyponitrous acid), which decomposes to nitrous oxide
and water. The disproportionation reaction of superoxide proceeds
with a relatively slow rate constant of≥2M−1 s−1 (and is presumably
why superoxide dismutase enzymes exist) while the dimerization
reaction of HNO proceeds with a rate constant of ∼8×106 M−1 s−1
[8]). For this reason, HNO is an inherently unstable molecule with
respect to decomposition and must be generated in situ from donor
compounds.
2. HNO donor compounds
Due to the ﬂeeting nature of nitroxyl, vis-à-vis dimerization and
formation of N2O, HNO must be generated in situ from donor
compounds (Table 1). The most common donor currently used is
Angeli's salt (AS), which releases HNO with a half-life of approxi-
mately 2–3 min at physiological pH and temperature. HNO release
from this compound is observed between pH 4–8. The mechanism
of HNO release from Angeli's salt has received a theoreticalNotes
- Fast release of HNO
- Nitrite is also formed
- Releases HNO only at high pH
- Releases HNO upon cleavage of ester bond
- Rate of HNO release is controlled by R substituent
- Reacts with thiols
- Primary amine “NONOate”
- NO donor at lower pH
- Releases HNO upon photoactivation
- Requires UV-A radiation (330–380 nm)
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yield HNO also produces one equivalent of nitrite. Nitrite is not an
innocuous bystander in physiological processes and reports on the
biological effects of nitrite are rapidly accumulating [9]. Thus the
formation of nitrite from Angeli's salt can be a confounding
component in studying HNO biology and pharmacology. Another
drawback to Angeli's salt use in a physiological context is the rapid
kinetics of decomposition and lends itself to almost a “bolus dose” of
HNO and nitrite. This can often be a technical problemwhen studying
biochemical and physiological processes that can be several orders of
magnitude slower. An often-overlooked chemical feature of Angeli's
salt decomposition is that theoretical calculations predict that a very
small amount of NO is produced [10].
Another long known HNO donor is Piloty's acid (or N-hydroxy-
benzene sulfonamide). Piloty's acid releases HNO upon deprotonation
and requires rather high pH to yield HNO. This is the major issue with
using Piloty's acid in biological studies as such high pH is rarely, if ever,
encountered [11]. However a potential area of research involves the
development of structural analogs of Piloty's acid that alter the HNO
release pH proﬁle by changing the electronic constituents on the
phenyl ring. It is hypothesized that electron withdrawing groups may
allow HNO release at more physiological conditions.
A new class of HNO donors, acyloxy nitroso compounds, has been
developed by King et al. that release HNO upon cleavage of the ester
bond [12]. Modifying the electronic and/or steric properties of the
acetyl group position changes the rate of ester cleavage and thus HNO
release. One of the major beneﬁts of these HNO donors, besides
controlling the HNO release rate, is that nitrite is not a product as is the
case with Angeli's salt. Another feature of these compounds that lends
itself to biochemical studies is the blue color that is a result of the
π→n electronic transition of the N–O bond. Thus biochemical reaction
kinetics can be easily monitored. As novel and exciting as these
compounds are, there are other reactions beyond HNO release. A
major route of decomposition in biological systems is the reactivity of
the donor compoundwith thiols. The characteristic blue color of these
compounds due to the N–O bond implies that the relatively low
energy LUMO is associated with this bond and is susceptible to
nucleophilic attack. Thus HNO release from these compounds must
compete with thiol reactivity at the electrophilic nitroso functional
group. Since the majority of HNO biochemistry and pharmacology is
associated with thiol reactions, the reactivity of “blue” HNO donors
with thiols may complicate the interpretation of cellular or in vivo
experiments. However the elegant chemistry of these compounds
makes it a very attractive choice for chemical and biochemical HNO
donation and future generations of “blue” compounds may limit the
thiol decomposition route.
Another potential HNO donor compound is IPA/NO, a primary
amine NONOate. NONOates of secondary amines have traditionally
been used as NO donors and have become the standard for NO
donating compounds in chemistry and biology. However primary
amine NONOates have the potential to release HNO under certain
conditions [11]. IPA/NO decomposition has received theoretical
consideration, and in concert with empirical observations, it is
currently agreed that HNO is released above pH 7.8 while IPA/NO is
believed to be exclusively a NO donor at pHb7 [13].
Temporal control of HNO release from a donor compound is a
feature that is lacking from the types of donors described above.
Compounds that release HNO via a retro-Diels–Alder reaction are
activated by UV-A light [14]. This gives researchers control over when
HNO is released and the only other product to consider from
decomposition is a primary amine. Despite the control of these
compounds with respect to HNO release, there have been no biolo-
gical reports using these compounds, perhaps due to the use of UV
irradiation.
While there are currently only a few reasonable HNO donors
available to researchers, it must be noted that the chemical,biochemical and physiological study of HNO is achievable, if not
readily straightforward. The use of multiple HNO donors in a study is
strongly encouraged due to the confounding factors of each HNO
donor (i.e. nitrite from Angeli's salt, thiol reactions of “blue”
compounds, NO release from IPA/NO). If multiple HNO donors are
used and elicit the same biological response, then it is safe to assume
that the effect is due to HNO as HNO release is the only common
characteristic of these diverse chemical compounds (Table 1). Thus
when it comes to HNO donors, fear not but be thorough.
3. HNO chemistry and biochemistry
The orthogonal relationship between NO and HNO was not
predicted from the literature prior to 2000. Rampant misconception
on the chemical nature of nitroxyl came from the reported pKa of 4.7,
which suggests that NO−, not HNO, was the most relevant species at
physiological concentration [15]. This also suggested that NO− and NO
would readily interconvert with reduction potential of NO to 3NO−
of +0.39 V and 1NO− of−0.2 V [16]. If these potentials were accurate,
NO should be rapidly converted to 3NO− which then would be
expected to react with O2 with diffusion controlled rate constants to
form peroxynitrite. This implies that NO would not be detectable in
biological systems and that peroxynitrite would be the primary
effector molecule of NOS metabolism. However, NO is directly
detected in vivo and from the enzymatic turnover of NOS [17–19].
Additional experiments showed that NO donors in vivo give different
effects than HNO donors indicating that these species do not
interconvert but rather have orthogonal and distinct processes [20].
These observations taken together required a re-examination of
the chemistry of HNO/NO−. Two studies using different methods re-
evaluated the pKa ﬁnding that it was 11.5 instead of 4.7 [8,21]. This
reverses several previous conceptions about nitroxyl. The ﬁrst is that
HNO, and not NO−, is the predominant species in vivo. The second is
that the reduction potential of NO is highb−0.8 V which is higher
than reducing system occurs in mammalian systems. This explains
why NO is not converted in vivo to NO− (and then to peroxynitrite via
reactionwith O2) and this, in part, explains the orthogonal behavior of
NO and HNO donors observed.
Though the revised pKa of 11.5 suggests that HNO and not NO− is
the dominant species at physiological pH, this does not discount the
possibility of the reactions involving the intermediacy of 3NO−.
Normally, reactions that are involved in acid base equilibrium, i.e.
protonation/deprotonation reactions, are so rapid that it does not
affect the overall kinetics of a reaction. However, it has been shown
that the deprotonation of HNO involves intersystem crossing (vibra-
tional relaxation from one energy state to a lower energy state of
differing quantum spin states) between 1HNO and 3NO−. This causes
the deprotonation reaction (HNO↔H++NO−) to be very slow
compared to a spin allowed process (e.g. 2 H2O↔H3O++OH−). This
slow deprotonation of HNO has effects on its overall reactivity. For
example 3NO− can react with O2 with rate constants of N109 M−1 s−1.
However at neutral pH, HNO is the predominant species and depro-
tonation to 3NO− proceeds with a rate constant of ∼105 M−1 s−1 and
HNO has a half-life of 5000 s [22]. It has been argued that the 3NO−/O2
reaction is not kinetically viable at neutral pH, even though the rate
constant for this reaction is near diffusion controlled, due to this spin-
forbidden deprotonation [20,22]. This kinetic barrier suggests that
HNO cannot be converted to 3NO− that could be converted to
peroxynitrite via oxygen reaction. Therefore, NO− and HNO have sufﬁ-
cient kinetic and thermodynamic barriers that they cannot be
interconverted. These vastly different chemical entities (HNO and
NO−) also display very different chemical reactivities. While NO−
predominately undergoes outer sphere electron transfer (much like
static electricity where the electron jumps from one atom to another)
and is therefore a nucleophile, HNO is a good electrophile preferring
addition reaction to nucleophiles, especially thiols, as opposed to
Table 2
Comparison of NO and HNO reactivity with biological reactants.
Biological
reactant
NO HNO
NO No reaction Forms N2O2−/HN2O2
unknown chemistry
HNO Forms N2O2−/HN2O2 unknown
chemistry
Dimerization and
decomposition to N2O
O2 Autoxidation leading to nitrosative
species (i.e. NO2 and N2O3)
Forms a potent 2 e−
oxidant that is not ONOO−
RSH/RS− No reaction Forms sulﬁnamide or
disulﬁde+H2NOH
Fe2+ heme Very stable Fe2+–NO Forms coordination
complexes
Fe3+ heme Forms unstable electrophilic nitrosyl;
ﬁrst step in reductive nitrosylation
Very stable Fe2+–NO
(except sGC)
Cu2+ No reaction Reduces Cu2+ to Cu+
yielding NO
Lipid radical Yields lipid—NO Yields lipid—H+NO
Fig. 2. Potential mechanisms of endogenous HNO formation. HNO has been postulated
to be formed from the enzymatic activity of nitric oxide synthase (NOS) in which the
substrate arginine is reduced by six electrons to yield HNO instead of ﬁve electrons to
yield NO. Another route is from the decomposition of nitrosothiol by thiols such as
glutathione. HNO can also be generated by the oxidation of hydroxylamine from the
peroxidase activity of heme proteins.
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as a hydrogen atom donor to high energy radicals such as a lipid
radical.
With this new chemical view of HNO, many of the biochemical
targets can be illuminated. The kinetics of HNO reactivity with a
number of potential biomolecules revealed that HNO reacts with ferric
heme proteins, CuZnSOD, MnSOD and thiols with bimolecular rate
constant of ∼106 M−1 s−1 [20,23]. HNO reacts with ferrous heme
proteins approximately 100 times slower (k=∼104 M−1 s−1) than
ferric heme proteins. Interestingly the rate constant for the reaction of
HNOwith O2 is b103 M−1 s−1, although the precise mechanism or the
intermediates of this reaction are not currently known [20,23]. In
contrast, NO reacts preferentially with ferrous heme protein and high-
energy radicals (e.g. lipid radicals, O2−) [24]. One feature of HNO is the
relatively weak H–N bond strength of ∼50 kcal/mol, making HNO a
decent H atom donor and thus able to quench high-energy radicals.
Indeed, HNO has been shown to inhibit lipid peroxidation in a yeast
model system, demonstrating that HNO also acts as an anti-oxidant
[25]. The differences in reactivity with biochemical targets suggest
that the biological orthogonality of NO and HNO can be rationalized
based on the chemical reactivity of these related but vastly different
chemical species, summarized in Table 2.
Given the preference of HNO to react with ferric heme proteins and
acidic thiols, this should guide investigators when studying the
biological effects of HNO. The facile and irreversible reaction between
HNO and the active site thiol of GAPDH represents a unique
biochemical molecular motif for further investigation [25]. Similarly,
HNO inhibits cathepsin B activity, which is a cysteine protease [26,27].
HNO also has been shown to react with metal bound thiolates, as
Angeli's salt was used to disrupt a yeast Cu–thiolate transcription
factor protein [28]. These examples demonstrate the reactive nature
of HNO in a biological setting by targeting critical reactive thiolates
(RS−). Other enzymes such as caspases, fatty acid acyl transferase and
ubiquitin ligases use acidic thiols in their respective catalytic
processes and are potential targets of HNO. Furthermore, calcium
channels, which are altered by HNO, have critical thiols that are
presumably the chemical motif that is responsible for the observed
effects of HNO. Additionally, metalloproteins are subject to reactivity
with HNO. These potential biochemical targets have not yet been
investigated, but represent a large body of work that needs to be
addressed in the development of HNO biochemistry and
pharmacology.
4. HNO in biological systems
Similar to nitric oxide, HNO has been shown to induce vasorelaxa-
tion. This effect has been known for some time as HNO, from either
Angeli's salt or cyanamide, a potent vasodilator similar to NO andEDRF [29,30]. HNO was also a candidate for EDRF, as thiol compounds
inhibit the vasorelaxation of EDRF, which is consistent with HNO
chemistry [31]. More recent work has shown that HNO is selectively a
venodilator in dogs [32]. In contrast, NO donors equally dilate both the
arterial and venous side of the circulatory system. Administration of
baroreceptor blockers resulted in balanced dilation suggesting that
the preference for AS mediated venodilationwas through constriction
of the arterial side through a sympathetic response [32]. The
molecular mechanisms of HNO mediated vasodilation have been
reported. Recent studies have shown that HNO mediates relaxation in
rodent models through a cGMP mechanism as well as modulating
voltage-gated potassium channels [33,34]. In rat coronary vasculature,
Angeli's salt is a potent vasodilatory agent by sGC dependent CGRP
release and by activating KATP channels [35]. Of clinical relevance, HNO
from Angeli's salt does not develop tolerance in isolated rat aorta,
which is a concernwith traditional therapies for angina pecoralis such
as nitroglycerin [36].
An important property of HNO in the cardiovascular system is
that HNO donors cause an increase in contractility in a canine model.
HNO has been shown to have positive inotropic (force of muscle
contraction) as well as lusitropic (relaxation of cardiac muscle)
properties; both properties contribute to increased cardiac output
[32]. Furthermore, in failing canine hearts, HNO also has positive
lusitropic and inotropic effects that are independent of beta-
adrenergic signaling [32]. Additionally, it was found that HNO
donors increased circulating CGRP levels, which increase the
contractility of the heart (positive inotropy) [32]. It was presumed
that CGRP was released from NANC neurons. However, under heart
failure conditions, CGRP did not play a major role in the HNO
induced contractility suggesting another molecular target [37].
Additional mechanisms for HNO induced contractility have been
proposed. Sarcoplasmic reticulum calcium cycling has been impli-
cated as HNO donors were shown to modulate the RyR2 receptors
and SERCA that result in increasing the contractility of isolated
cardiomyocytes [38]. Mechanistically, HNO has been shown to target
a critical cysteine residue of SERCA (cysteine 674) that causes an
increase in SERCA activity [39]. Furthermore, SERCA2a activation can
be achieved by phosphorylating phospholamban (PLN) via PKA
signaling. However, recently it has been shown that also HNO is able
to increase SERCA2a activity by modifying critical thiols in PLN,
removing its inhibition on the Ca2+ pump achieved by [40].
Additionally, HNO alters myoﬁlament–Ca2+ interaction and results
in increased cardiac contraction force [41]. Collectively, these
ﬁndings indicate that nitroxyl may have a positive effect in heart
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more this represents opportunity to develop HNO donors for the
pharmacological treatment of heart failure.
HNO has been shown to have effects in the realm of ischemia
reperfusion (IR) injury. IR injury occurs when tissue is deprived of
adequate blood ﬂow for a period of time causing among other effects
hypoxia, which is the ischemic event. The reperfusion of oxygenated
blood causes the injury and results in necrosis of the tissue. IR injury
can be alleviated by preconditioning the tissue, which involves brief
occlusions of the vasculature prior to the actual cessation of blood
ﬂow. NO donors have been shown to be protective in cardiac ischemia
reperfusion injury when given during the reperfusion phase [42].
However, HNO administration during reperfusion was found to
dramatically increase the infarct size. These results again indicate
that in vivo, NO and HNO have very different effects [43]. However,
additional studies have shown that HNO is a powerful preconditioning
agent. Pre-treating hearts with Angeli's salt followed by an ischemic
event results in a dramatic decrease in the infarct size [44]. These in
vivo results clearly suggest that HNO and NO donors have very
different pharmacological effects.
In addition to cardiovascular effects, HNO has shown promising
anti-cancer effects. Most solid tumors thrive in hypoxic conditions and
rely upon glycolysis as a major energy source. One of the critical
enzymes in the glycolytic pathway is GAPDH. HNO has been shown to
inhibit GAPDH activity in an irreversible manner [45]. Furthermore,
HNO inhibits breast and neuroblastoma cancer proliferation in mouse
xenografts as well as in vitro cultures [46,47]. HNO also caused an
increase of apoptosis in the breast cancer xenografts and inhibited
tumor angiogenesis [46]. In addition to the direct effects of HNO on
cancer cells, HNO donors may be useful adjuvant agents to cancer
chemotherapy. Angeli's salt has been shown to inhibit poly(ADP-
Ribose) polymerase (PARP) in a breast cancer cell line [48]. PARP is an
important component of the DNA repair machinery and is thus a
potentially important molecular target in the treatment of cancer,
since a number of chemotherapies and radiation therapy are based on
inducing DNA damage of the cancer cell. Inhibition of PARP by HNO
donors would then increase the efﬁcacy of these therapies. These
observations indicate that HNO donors may be effective agents in
cancer chemotherapy.
Due to the unique physiological properties of HNO, the endogen-
ous formation of HNO in vivo is an intriguing possibility and one that
has been suggested for several decades. A number of potential
mechanisms have been proposed for the endogenous production of
HNO (Fig. 2); however no mechanism has been clearly established to
date, mainly due to a lack of detection (vide infra). Several studies
implicated that HNO could be an intermediate in catalytic process of
nitric oxide synthase (NOS) [49–51]. Detection of N2O and NH2OH,
products of HNO metabolism, was an indication that HNO was part of
the enzymatic turnover of NOS [50,52]. Furthermore, the presence of
CuZnSOD caused an increase in NO fromNOS [53]. Also, Fe(II)–NOwas
observed to be formed during enzymatic turnover in NOS which is
normally in a ferric resting state. Taken together, these ﬁndings imply
that nitroxyl could be an intermediate in the metabolism of NOS,
however this has not been conclusively established.
Another potential mechanism of HNO generation in biological
systems is through the decomposition of RSNO. Thioredoxin has been
shown to generate HNO and NH2OH though the reduction of these
adducts [54]. HNO is also formed from the nitrosation of dithiol
compounds (i.e. DTT and lipoic acid) [55]. Thus one of the secondary
products of nitrosative stress involves the intermediacy of HNO and
eventually NH2OH. These processes have not yet been established in
vivo, but the chemistry implies that RSNO is not an evolutionary
signalingmotif like phosphorylation, as has been suggested, due to the
reactivity of excess thiols to form disulﬁde and HNO [56].
The oxidation of NH2OH is another potential source of HNO. The
two-electron oxidation of NH2OHwhose oxidation potential is +0.7 V(vs. Ag/AgCl) results in HNO. The generation of high-valent iron–oxo
complexes from the reaction of hydrogen peroxide with ferric hemes
can oxidize NH2OH to HNO [55]. The formation of glutathione
sulﬁnamide was used as a marker of HNO migration from the heme
pocket [55]. Since the resulting ferric heme that is formed after the
oxidation of hydroxylamine can react with HNO to form a ferrous
nitrosyl complex, there is some question as to whether HNOwould be
capable of escaping the heme pocket to react with another substrate. A
survey of heme proteins showed that Mb and MPO having proximal
histidine residues to the heme site could generate HNO that is able to
migrate from the heme pocket. Interestingly, HNO activity has been
primarily shown to be associated with the heart and under conditions
of inﬂammation where hydrogen peroxide generation is known.
One of the current challenges with expanding HNO research is in
developing reliable detection methods of HNO generation and/or
reactivity in vivo. Currently, the formation of N2O and NH2OH are used
to indicate that HNO is involved in a particular process; however this
is only indirect evidence of nitroxyl. The formation of sulﬁnamidewith
proteins such as GAPDH may provide a unique footprint for the
formation and activity of this compound [45,57]. Recently a novel
proteomic approach offers a potentially very useful tool in analyzing
the reactive targets of HNO from ex vivo samples [58]. The
development of analytical methods is critically needed for this
promising pharmacological agent to advance.
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